Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue: 2018-2024

Historic Non-Current Deffered Revenue for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $91.5 million.

  • Bicycle Therapeutics' Non-Current Deffered Revenue fell 24.22% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 24.22%. This contributed to the annual value of $91.5 million for FY2024, which is 17.01% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Non-Current Deffered Revenue of $91.5 million as of FY2024, which was down 17.01% from $110.2 million recorded in FY2023.
  • Over the past 5 years, Bicycle Therapeutics' Non-Current Deffered Revenue peaked at $110.2 million during FY2023, and registered a low of $25.0 million during FY2020.
  • Over the past 3 years, Bicycle Therapeutics' median Non-Current Deffered Revenue value was $91.5 million (recorded in 2024), while the average stood at $81.0 million.
  • In the last 5 years, Bicycle Therapeutics' Non-Current Deffered Revenue spiked by 407.63% in 2020 and then dropped by 20.38% in 2022.
  • Bicycle Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $25.0 million in 2020, then soared by 108.09% to $52.1 million in 2021, then fell by 20.38% to $41.5 million in 2022, then soared by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024.